Actos, also known a pioglitazone, is a prescription medication approved for treatment of type 2 diabetes. Plaintiffs allege that individuals who used Actos face an increased risk of developing bladder cancer. In addition, Plaintiffs allege that the defendants concealed their knowledge of this risk and failed to provide adequate warnings to consumers and the health care community.
The cases have being consolidate in the US District of Western Louisiana under MultiJurisdtiction Litigation NO. 2299.
- stomach pain, blood in your urine;
- painful urination;
- feeling short of breath, even with mild exertion;
- swelling or rapid weight gain;
- chest pain, general ill feeling;
- nausea, upper stomach pain, itching, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes);
- blurred vision;
- increased thirst or hunger, urinating more than usual; or
- pale skin, easy bruising or bleeding, weakness.
- cold symptoms such as stuffy nose, sneezing, cough, sore throat;
- gradual weight gain;
- muscle pain;
- back pain; or
- tooth problems.
Do you think you have a case? 410-849-9529
Nationwide Toll Free (800) 932-0979
If you developed bladder cancer after taking Actos you may have a claim. Attorney Joseph K. Githuku is prepared to help Actos cancer patients protect their legal rights and demand the compensation they deserve for their injuries and losses.
To reitarate, the drug manufacturers are accused of failing to warn about side effects and willfully concealing the safety concerns with the drug. As in any other cases for personal injury, plaintiff’s are entitled to recover:
- Medical expenses paid whether paid by plaintiffs or their behalf
- Pain and suffering
- Loss of capacity or use of parts of their body
- Lost wages
- Lost earning capacity
- Wrongful death
A federal jury in one of the first Actos cases to go to trial ordered the manufacturers, Takeda and Lilly, to pay a $1.5 million in compensatory damages and $9 billion in punitive damages to the plaintiff according to Bloomberg News. The jury deliberated for four hours before concluding that Takeda failed to adequately warn users about the bladder cancer risks